^
    Apply
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 (NCT06846099)
    Phase 1
    Risen (Suzhou) Pharma Tech Co., Ltd.
    Recruiting
    Last update posted :
    02/25/2025
    Initiation :
    12/07/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    PIK3CA
    |
    PIK3CA mutation
    Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients (NeoCARD) (NCT06845319)
    Phase 2
    Medical University of South Carolina
    Not yet recruiting
    Last update posted :
    02/25/2025
    Initiation :
    06/01/2025
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    BRCA
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/20/2017
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    ER • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive
    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (NCT03191149)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/25/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-1 • CTLA4
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer (NRG-GY026) (NCT05256225)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/16/2022
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    HER-2 • TP53
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (S2206) (NCT06058377)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • ER • PGR
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin
    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE) (NCT05607004)
    Phase 2
    Atossa Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/14/2023
    Primary completion :
    02/01/2026
    Completion :
    09/01/2026
    HER-2 • ER
    |
    HER-2 negative
    |
    exemestane • goserelin acetate
    The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (NCT03659136)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    11/28/2018
    Primary completion :
    08/30/2021
    Completion :
    05/11/2022
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    everolimus • exemestane • xentuzumab (BI-836845)
    Evaluation of Vaginal Microbiome As a Biomarker for the Improvement of Vaginal Health in Women with Breast Cancer, ARISE Study (NCT05946668)
    Phase N/A
    Ohio State University Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/06/2023
    Primary completion :
    05/30/2025
    Completion :
    05/30/2025
    HER-2
    A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) (NCT02637687)
    Phase 1/2
    Bayer
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/16/2015
    Primary completion :
    07/20/2024
    Completion :
    09/30/2026
    NTRK3 • ETV6 • NTRK
    |
    NTRK positive • NTRK fusion
    |
    carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (NCT05063786)
    Phase 3
    Spanish Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/14/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2 • ER • PIK3CA • PGR
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (KEYNOTE-797) (NCT04042701)
    Phase 1
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/10/2020
    Primary completion :
    07/01/2025
    Completion :
    08/01/2025
    EGFR • HER-2 • BRAF • ALK • ROS1
    |
    HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion
    |
    Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    BRCA Mutations in Latinas (NCT01251900)
    Phase N/A
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    07/07/2011
    BRCA
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal
    Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA) (NCT04906395)
    Phase 3
    Tolmar Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/01/2021
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    HER-2
    |
    HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/07/2023
    Primary completion :
    07/01/2030
    Completion :
    07/01/2030
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • Tasigna (nilotinib) • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical
    Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation (ELAINE 3) (NCT05696626)
    Phase 3
    Sermonix Pharmaceuticals Inc.
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/31/2023
    Primary completion :
    04/01/2027
    Completion :
    04/01/2028
    ER
    |
    ESR1 mutation
    |
    Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)
    Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage (NCT05554211)
    Phase 2
    Northwestern University
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    07/12/2022
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    BRCA
    A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA) (NCT05963997)
    Phase 1/2
    Carrick Therapeutics Limited
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/09/2023
    Primary completion :
    12/23/2025
    Completion :
    12/23/2025
    HER-2 • ER • TP53 • CDK4
    |
    TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation
    |
    Orserdu (elacestrant) • samuraciclib (CT7001)
    A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC) (NCT05963984)
    Phase 2
    Carrick Therapeutics Limited
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/14/2023
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    HER-2 • ER • TP53 • CDK4
    |
    TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    fulvestrant • samuraciclib (CT7001)
    Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial (NCT06184750)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/27/2024
    Primary completion :
    07/30/2027
    Completion :
    07/30/2027
    ADAR
    |
    tamoxifen
    Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (NCT05941520)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/23/2024
    Primary completion :
    08/23/2027
    Completion :
    09/01/2028
    TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2
    |
    TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    tamoxifen • acolbifene
    Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (NCT04886531)
    Phase 2
    Ruth O'Regan
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/21/2022
    Primary completion :
    09/01/2025
    Completion :
    10/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study (NCT00006421)
    Phase N/A
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    10/25/2000
    BRCA1 • BRCA2 • BRCA
    |
    BRCA mutation
    Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease (NCT03808337)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/16/2019
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • HER-2 • ALK • ROS1
    Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhibition and Radiation (NCT05491226)
    Phase 2
    Stephen Shiao
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/17/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • PD-L1
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    Endoxifen in Adults With Hormone Receptor Positive Solid Tumors (NCT01273168)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2011
    Primary completion :
    06/01/2020
    Completion :
    06/01/2026
    HER-2
    |
    tamoxifen • Zonalta (Z-endoxifen hydrochloride)
    Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects (FLAMINGO-01) (NCT05232916)
    Phase 3
    Greenwich LifeSciences, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/11/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2 • HLA-A
    |
    HLA-A*02 positive
    |
    Herceptin (trastuzumab) • GLSI-100 • GP2
    An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin (NCT00923104)
    Phase N/A
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    04/23/2009
    IL6 • TNFA • IL1B • MMP1
    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
    Phase 2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/01/2018
    Primary completion :
    06/01/2020
    Completion :
    02/09/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (NCT06195306)
    Phase 2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/28/2025
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    FOXA1 • AGR2 • LEP
    |
    tamoxifen
    Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer (HeNRIetta) (NCT02515110)
    Phase N/A
    Virginia Commonwealth University
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/04/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • ER • PGR
    Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (NCT04052555)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/24/2020
    Primary completion :
    11/20/2025
    Completion :
    11/20/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    berzosertib (M6620)
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation
    |
    Halaven (eribulin mesylate) • Aliqopa (copanlisib)
    Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCI-2021-11793) (NCT05111561)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/21/2025
    Initiation :
    08/02/2022
    Primary completion :
    03/14/2025
    Completion :
    03/14/2025
    HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1
    |
    BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion
    |
    Mektovi (binimetinib) • ZEN-3694
    A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies (REMERGE) (NCT06274515)
    Phase 4
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/02/2024
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    HER-2 • PD-L1 • ER • CDK4
    A Study of SGN-PDL1V in Advanced Solid Tumors (SGNPDL1V-001) (NCT05208762)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/25/2022
    Primary completion :
    11/18/2027
    Completion :
    11/17/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • PF-08046054
    Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (NCT05573126)
    Phase 1/2
    Ellipses Pharma
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/11/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2026
    HER-2
    |
    HER-2 negative
    |
    everolimus • Orserdu (elacestrant) • vosilasarm (EP0062)
    First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (STX-478-101) (NCT05768139)
    Phase 1/2
    Scorpion Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/17/2023
    Primary completion :
    02/28/2027
    Completion :
    02/28/2029
    PIK3CA
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • Kisqali (ribociclib) • fulvestrant • STX-478